Teva Pharmaceutical Industries (NYSE:TEVA) Given New $23.00 Price Target at UBS Group

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) had its target price decreased by UBS Group from $24.00 to $23.00 in a research note issued to investors on Thursday,Benzinga reports. The firm currently has a "buy" rating on the stock. UBS Group's price objective would suggest a potential upside of 37.27% from the stock's previous close.

TEVA has been the subject of several other research reports. Truist Financial began coverage on Teva Pharmaceutical Industries in a report on Wednesday, May 28th. They issued a "buy" rating and a $25.00 price objective for the company. The Goldman Sachs Group initiated coverage on Teva Pharmaceutical Industries in a research note on Friday, June 6th. They issued a "buy" rating and a $24.00 price target for the company. Hsbc Global Res raised shares of Teva Pharmaceutical Industries to a "strong-buy" rating in a research note on Monday, April 28th. Wall Street Zen raised shares of Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a research note on Thursday, May 22nd. Finally, JPMorgan Chase & Co. raised shares of Teva Pharmaceutical Industries from a "neutral" rating to an "overweight" rating and lifted their price objective for the company from $21.00 to $23.00 in a research report on Monday, May 12th. Eight research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, Teva Pharmaceutical Industries currently has an average rating of "Buy" and a consensus price target of $24.13.

Teva Pharmaceutical Industries Stock Up 1.2%

Shares of TEVA stock traded up $0.20 during trading hours on Thursday, hitting $16.76. 8,942,158 shares of the company were exchanged, compared to its average volume of 10,289,327. The business has a 50 day moving average of $16.72 and a two-hundred day moving average of $17.40. The company has a market capitalization of $19.22 billion, a PE ratio of -14.57, a PEG ratio of 0.86 and a beta of 0.60. The company has a current ratio of 1.03, a quick ratio of 0.74 and a debt-to-equity ratio of 2.59. Teva Pharmaceutical Industries has a 52 week low of $12.47 and a 52 week high of $22.80.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The company reported $0.52 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.47 by $0.05. The business had revenue of $3.89 billion during the quarter, compared to the consensus estimate of $3.99 billion. Teva Pharmaceutical Industries had a positive return on equity of 45.44% and a negative net margin of 7.74%. Teva Pharmaceutical Industries's quarterly revenue was up 1.9% on a year-over-year basis. During the same period last year, the company earned $0.48 earnings per share. Analysts anticipate that Teva Pharmaceutical Industries will post 2.5 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, EVP Matthew Shields sold 6,206 shares of the business's stock in a transaction that occurred on Tuesday, June 3rd. The stock was sold at an average price of $17.02, for a total transaction of $105,626.12. Following the completion of the sale, the executive vice president now owns 9,989 shares in the company, valued at $170,012.78. The trade was a 38.32% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 0.55% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Teva Pharmaceutical Industries

A number of institutional investors have recently made changes to their positions in TEVA. Oarsman Capital Inc. bought a new stake in Teva Pharmaceutical Industries in the 4th quarter valued at about $29,000. Marshall & Sterling Wealth Advisors Inc. bought a new stake in shares of Teva Pharmaceutical Industries in the fourth quarter valued at approximately $44,000. Golden State Wealth Management LLC bought a new stake in shares of Teva Pharmaceutical Industries in the first quarter valued at approximately $39,000. New Age Alpha Advisors LLC bought a new stake in shares of Teva Pharmaceutical Industries during the 1st quarter valued at $43,000. Finally, Compagnie Lombard Odier SCmA bought a new stake in shares of Teva Pharmaceutical Industries during the 1st quarter valued at $54,000. Institutional investors own 54.05% of the company's stock.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.